Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of November 2024, with a specific reporting date of November 22, 2024. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by a Person Discharging Managerial Responsibilities (PDMR). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. The only financial data provided relates to a specific executive share transaction:
- Transaction Date: November 21, 2024
- Instrument: Haleon Ordinary Shares (GB00BMX86B70)
- Acquisition Volume: 158,653 shares (acquired at nil cost as part of a Share Value Plan buyout award)
- Disposal Volume: 74,678.93 shares (sold to cover tax obligations)
- Disposal Price: £3.718 per share
- Retained Shares: 83,974.07 shares (subject to a two-year holding period)
Material Changes
There are no material changes to the company's business operations or financial position reported in this filing. The document solely reports a change in the shareholding of Dawn Allen, Chief Financial Officer, resulting from the vesting of an award granted upon her joining the company to compensate for forfeited incentives from previous employment.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on market outlook, or discussion of corporate risks. It notes that the award is subject to malus and clawback provisions. The transaction was executed outside a trading venue for the acquisition and on the London Stock Exchange (XLON) for the tax-related disposal.
Key Facts for Investor Verification
- Verify the total shareholding of Dawn Allen, CFO, following the vesting and tax sale.
- Confirm the two-year holding period restrictions on the 83,974.07 retained shares.
- Note that the acquisition price was nil, reflecting a non-cash compensation adjustment rather than a market purchase.
- Understand that this filing does not reflect Haleon's quarterly or annual financial performance.